BRPI0917656A2 - Fatores viii e ix humanos produzidos de forma recombinante - Google Patents

Fatores viii e ix humanos produzidos de forma recombinante

Info

Publication number
BRPI0917656A2
BRPI0917656A2 BRPI0917656A BRPI0917656A BRPI0917656A2 BR PI0917656 A2 BRPI0917656 A2 BR PI0917656A2 BR PI0917656 A BRPI0917656 A BR PI0917656A BR PI0917656 A BRPI0917656 A BR PI0917656A BR PI0917656 A2 BRPI0917656 A2 BR PI0917656A2
Authority
BR
Brazil
Prior art keywords
recombinantly produced
human factors
produced human
factors viii
protein
Prior art date
Application number
BRPI0917656A
Other languages
English (en)
Inventor
Sandberg Helena
Stenlund Peter
Schröder Carola
Casademunt Elisabeth
Tiemeyer Maya
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of BRPI0917656A2 publication Critical patent/BRPI0917656A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROTEÍNA DO FATOR VIII OU IX HUMANO RECOMBINANTE, BEM COMO COMPOSIÇÃO FARMACÊUTICA, COMPLEXO E USO DA MESMA. A presente invenção refere-se a uma proteína do fator VIII ou IX humano recombinante que possui um padrão de glicosilação humano, porém a proteína é desprovida de ácido N-glicolilneuramínico e/ou do grupo de carboidrato Gal(Alfa)-3Gal.
BRPI0917656A 2008-08-21 2009-08-21 Fatores viii e ix humanos produzidos de forma recombinante BRPI0917656A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13625008P 2008-08-21 2008-08-21
EP08162765 2008-08-21
PCT/EP2009/060829 WO2010020690A1 (en) 2008-08-21 2009-08-21 Recombinantly produced human factor viii and ix

Publications (1)

Publication Number Publication Date
BRPI0917656A2 true BRPI0917656A2 (pt) 2017-07-11

Family

ID=40317066

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917656A BRPI0917656A2 (pt) 2008-08-21 2009-08-21 Fatores viii e ix humanos produzidos de forma recombinante

Country Status (13)

Country Link
US (1) US9120873B2 (pt)
EP (1) EP2331569A1 (pt)
JP (1) JP2012500250A (pt)
KR (1) KR101921698B1 (pt)
CN (1) CN102119172A (pt)
AU (1) AU2009284113B2 (pt)
BR (1) BRPI0917656A2 (pt)
CA (1) CA2732423A1 (pt)
IL (1) IL210852A (pt)
MX (1) MX2011001624A (pt)
RU (1) RU2011110459A (pt)
WO (1) WO2010020690A1 (pt)
ZA (1) ZA201102020B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110385A1 (es) 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
CA2796729C (en) 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
PL3552619T3 (pl) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
ES2970057T3 (es) 2011-05-13 2024-05-24 Octapharma Ag Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
EP2822577B1 (en) * 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
HK1213521A1 (zh) 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015270394B2 (en) 2014-06-06 2017-12-21 Octapharma Ag Preparation comprising Factor VIII and Von Willebrand factor peptides

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
GB9010742D0 (en) 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5316680A (en) 1992-10-21 1994-05-31 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for using same
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AUPO871997A0 (en) 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
JP2003511082A (ja) * 1999-10-12 2003-03-25 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 第ｖｉｉｉ因子をコードするアデノ随伴ウィルスベクターとその使用法
EP1136553A1 (en) 2000-03-22 2001-09-26 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
EE200200538A (et) 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
WO2005121163A2 (en) 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
US7365310B2 (en) 2005-06-27 2008-04-29 Agilent Technologies, Inc. Increased depth of field for high resolution imaging for a matrix-based ion source
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20070092482A1 (en) 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer
AR062069A1 (es) 2006-07-14 2008-10-15 Genentech Inc Replegado de proteinas recombinantes
US20080207487A1 (en) 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
AU2008209985A1 (en) * 2007-02-01 2008-08-07 Baxter Healthcare S.A. Improved fix-mutant proteins for hemophilia B treatment
CN101730707B (zh) 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
EP2220108A2 (en) 2007-11-15 2010-08-25 Novo Nordisk A/S Protein purification and endotoxin removal
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN101260145B (zh) 2008-04-11 2012-08-08 天津溥瀛生物技术有限公司 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
MX2011003074A (es) 2008-09-24 2011-04-19 Stabilitech Ltd Metodo para conservar polipeptidos utilizando un azucar y polietilenimina.

Also Published As

Publication number Publication date
CA2732423A1 (en) 2010-02-25
KR20110057131A (ko) 2011-05-31
ZA201102020B (en) 2011-12-28
KR101921698B1 (ko) 2018-11-26
IL210852A (en) 2014-06-30
WO2010020690A1 (en) 2010-02-25
US9120873B2 (en) 2015-09-01
AU2009284113A1 (en) 2010-02-25
RU2011110459A (ru) 2012-09-27
IL210852A0 (en) 2011-04-28
JP2012500250A (ja) 2012-01-05
EP2331569A1 (en) 2011-06-15
MX2011001624A (es) 2011-03-28
US20110262424A1 (en) 2011-10-27
CN102119172A (zh) 2011-07-06
AU2009284113B2 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
BRPI0917656A2 (pt) Fatores viii e ix humanos produzidos de forma recombinante
BR112012014065A2 (pt) escova de dentes
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BRPI0910461A2 (pt) fsh recombinante incluindo sialilação alfa 2,3 e alfa 2,6
ES2559007T3 (es) Alfa1 antitripsina humana recombinante
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
CR20110509A (es) Composicion farmaceutica
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
MX2012002139A (es) Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.
BR112014009528A8 (pt) métodos e composições para tratar eritropoiese ineficaz
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112012007563A2 (pt) peptídeos sintéticos antagonistas de miostatina
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
UY33258A (es) Proteinas de union a antigeno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL